Ország: Ausztrália
Nyelv: angol
Forrás: Department of Health (Therapeutic Goods Administration)
clozapine, Quantity: 100 mg
Viatris Pty Ltd
Tablet, uncoated
Excipient Ingredients: lactose monohydrate; colloidal anhydrous silica; maize starch; purified talc; magnesium stearate; povidone
Oral
100 x 100 mg tablets, 28 tablets, 50 x 100mg tablets
(S4) Prescription Only Medicine
CLOZAPINE MYLAN is indicated in treatment-resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to, or intolerant of other antipsychotic drugs. Non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. Intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).
Visual Identification: Yellow flat circular tablet with bevelled edge, 10 mm in diameter, angle scored, marked "ZA" on one side and "SANDOZ" on the other.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 5 Years; Container Temperature: Store below 30 degrees Celsius
Registered
2020-01-10